Celyad Oncology SA
CLYYF
$0.25
-$0.10-28.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -95.53% | -95.66% | 5.33% | -2.63% | 193.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.53% | -95.66% | 5.33% | -2.63% | 193.91% |
| Cost of Revenue | -100.00% | -100.00% | -6.25% | -14.29% | -88.15% |
| Gross Profit | -95.45% | -95.59% | 25.93% | 18.52% | 406.18% |
| SG&A Expenses | 56.97% | 52.86% | 1.93% | -6.30% | -44.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2,912.99% | -2,834.69% | 44.78% | 49.20% | -216.81% |
| Total Operating Expenses | -181.99% | -179.84% | 24.85% | 14.77% | -38.84% |
| Operating Income | 187.32% | 185.03% | -24.93% | -14.85% | 41.69% |
| Income Before Tax | 276.97% | 272.33% | -27.30% | -17.03% | 42.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 276.97% | 272.33% | -27.30% | -17.03% | 41.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 276.97% | 272.33% | -27.30% | -17.03% | 41.53% |
| EBIT | 187.32% | 185.03% | -24.93% | -14.85% | 41.69% |
| EBITDA | 190.39% | 192.24% | -27.42% | -17.14% | 42.25% |
| EPS Basic | 265.92% | 261.79% | -33.42% | -17.04% | 59.23% |
| Normalized Basic EPS | 180.80% | 178.79% | -34.04% | -17.27% | 59.86% |
| EPS Diluted | 243.30% | 239.84% | -33.42% | -17.04% | 59.23% |
| Normalized Diluted EPS | 169.64% | 167.97% | -34.04% | -17.27% | 59.86% |
| Average Basic Shares Outstanding | 6.52% | 6.52% | -4.73% | 0.00% | 43.60% |
| Average Diluted Shares Outstanding | 23.36% | 23.36% | -4.73% | 0.00% | 43.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |